Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus LAMICTAL CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus LAMICTAL CD.
CENOBAMATE vs LAMICTAL CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Lamotrigine is a phenyltriazine anticonvulsant that stabilizes neuronal membranes by blocking voltage-sensitive sodium channels and inhibiting the presynaptic release of excitatory neurotransmitters such as glutamate and aspartate.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
Lamotrigine extended-release (LAMICTAL CD) for epilepsy: initial 50 mg orally once daily for 2 weeks, then 100 mg once daily for 2 weeks, then 200 mg once daily for 2 weeks, then 300 mg once daily for 2 weeks, then 400 mg once daily thereafter. For bipolar disorder: initial 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 2 weeks, then 200 mg once daily thereafter.
None Documented
None Documented
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Terminal elimination half-life in adults is approximately 25.4 hours (range 14-50 hours) in healthy volunteers; reduced to 14.5 hours (range 12-20) with enzyme-inducing antiepileptics (e.g., carbamazepine, phenytoin), increased to 59 hours (range 30-90) with valproate, and prolonged in renal impairment.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Lamotrigine is primarily eliminated by hepatic metabolism, with approximately 94% of the dose excreted in urine as glucuronide conjugates (10% as unchanged drug) and 2% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant